Fosigotifator + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALS
Conditions
ALS, Amyotrophic Lateral Sclerosis
Trial Timeline
Sep 22, 2021 → Jul 15, 2025
NCT ID
NCT04948645About Fosigotifator + Placebo
Fosigotifator + Placebo is a phase 1 stage product being developed by AbbVie for ALS. The current trial status is terminated. This product is registered under clinical trial identifier NCT04948645. Target conditions include ALS, Amyotrophic Lateral Sclerosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06618118 | Phase 1 | Terminated |
| NCT04948645 | Phase 1 | Terminated |
Competing Products
20 competing products in ALS